In this thought-provoking episode, Matt challenges the current narrative surrounding GLP-1 medications (like Ozempic and Wegovy) and obesity treatment. He poses a crucial question: Are we focusing too much on survival instead of helping people truly thrive?Key Points: • The difference between surviving and thriving in healthcare • Why treating obesity as purely a genetic disease might be misguided • Three major concerns about GLP-1 medications:Downstream effects (vitamin absorption, gut health, muscle loss)Loss of essential healthy habitsNo clear exit strategy from the medication

Ver todos los episodios